Drug intelligence / Profile preview

QRL-TBA

Development stage: Preclinical
Lead developer: QurAlis

Overview

QRL-TBA is a placeholder designation for preclinical therapeutic programs under development by QurAlis. One program is focused on Fragile X syndrome and targets the Fragile X messenger ribonucleoprotein 1 (FMR1) gene or protein. A second program is directed toward progressive supranuclear palsy (PSP) with an undisclosed molecular target. QurAlis is a biotechnology company specializing in precision medicines for neurodegenerative and neurodevelopmental diseases, often employing modalities such as antisense oligonucleotides or small molecules to modulate disease-relevant genetic pathways.

Targets

FMR1 (Fragile X messenger ribonucleoprotein 1)

Beyond the preview

Go deeper on QRL-TBA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QRL-TBA.

Explore the full profile